Case report: A p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma

Familial Cancer

Volumn 11, Issue 1, 2012, Pages 131-136

  Qi, X P ^a   Ying, R B ^b   Ma, J M ^a   Liu, W T ^c   Du, Z F ^c   Fei, J ^a   Yang, C P ^a   Song, Q Z ^a   Jin, H Y ^a   Chen, Z G ^a   Han, J S ^a   Wang, J Q ^a   Chen, X L ^c   Zhao, Y ^c   Lu, J J ^c   Zhang, X N ^c  

^a The 117th PLA Hospital   (China)

^b Tumor Hospital of Taizhou   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Familial medullary thyroid carcinoma; Mutation; Phenotype; Polymorphism; RET

Indexed keywords

CALCITONIN; PROTEIN RET;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER SIZE; CHINESE; CLINICAL ARTICLE; FAMILIAL CANCER; FAMILIAL MEDULLARY THYROID CARCINOMA; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; HETEROZYGOTE; HUMAN; LYMPH NODE DISSECTION; NECK DISSECTION; PEDIGREE; PHENOTYPE; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROIDECTOMY; TREATMENT REFUSAL;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; FEMALE; GERM-LINE MUTATION; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; PEDIGREE; PHENOTYPE; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS; THYROIDECTOMY; YOUNG ADULT;

EID: 84858293686     PISSN: 13899600     EISSN: 15737292     Source Type: Journal    
DOI: 10.1007/s10689-011-9487-1     Document Type: Article

References (23)

1. Kloos RT, Eng C et al (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19:565-612
2. Qi XP, Ma JM et al (2011) RET germline mutations identified by exome sequencing in a Chinese multiple endocrine neoplasia type 2A/familial medullary thyroid carcinoma family. Plos One 6:e20353
3. Eng C, Clayton D et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276:1575-1579 (Pubitemid 26384740)
4. Raue F, Frank-Raue K (2010) Update multiple endocrine neoplasia type 2. Fam Cancer 9:449-457
5. Frank-Raue K, Rondot S, Raue F (2010) Molecular genetics and phenomics of RET mutations: impact on prognosis of MTC. Mol Cell Endocrinol 322:2-7
6. Pierotti MA, Santoro M et al (1992) Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci 89:1616-1620
7. Donis-Keller H, Dou S et al (1993) Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856 (Pubitemid 23216611)
8. Eng C, Mulligan L (1997) Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease. Hum Mutat 9:97-109 (Pubitemid 27133173)
9. Jung J, Uchino S et al (2010) A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation. J Korean Med Sci 25:226-229
10. Hofstra RM, Fattoruso O et al (1997) A novel point mutation in the intracellular domain of the RET protooncogene in a family with medullary thyroid carcinoma. J Clin Endocrinol Metab 82:4176-4178 (Pubitemid 27525535)
11. Dabir T, Hunter SJ et al (2006) The RET mutation E768D confers a late-onset familial medullary thyroid carcinoma-only phenotype with incomplete penetrance: implications for screening and management of carrier status. Fam Cancer 5:201-204 (Pubitemid 43824478)
12. Kameyama K, Okinaga H, Takami H (2004) RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. Biomed Pharmacother 58:345-347 (Pubitemid 38951066)
13. Da Silva AM, Maciel RM et al (2003) A novel germ-line point mutation in RET exon 8 (Gly533Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88:5438-5443 (Pubitemid 37452751)
14. Pinna G, Orgiana G et al (2007) RET proto-oncogene in Sardinia: V804 M is the most frequent mutation and may be associated with FMTC/MEN-2A phenotype. Thyroid 17:101-104
15. Castellone MD, Verrienti A et al (2010) A novel de novo germ-line V292 M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization. Clin Endocrinol (Oxf) 73:529-534
16. Ceccherini I, Hofstra RM et al (1994) DNA polymorphisms and conditions for SSCP analysis of the 20 exons of the ret protooncogene. Oncogene 9:3025-3029
17. Elisei R, Cosci B et al (2004) RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 89:3579-3584 (Pubitemid 38951937)
18. Borrego S, Saez ME et al (1999) Specific polymorphisms in the RET proto-oncogene are over-represented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. J Med Genet 36:771-774 (Pubitemid 29462322)
19. Lesueur F, Corbex M et al (2002) Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma. J Med Genet 39:260-265 (Pubitemid 34496802)
20. Robledo M, Gil L et al (2003) Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 63:1814-1817 (Pubitemid 36460842)
21. Baumgartner-Parzer SM, Lang R et al (2005) Polymorphisms in Exon 13 and Intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? J Clin Endocrinol Metab 90:6232-6236 (Pubitemid 41606549)
22. Morrison PJ, Atkinson AB (2009) Genetic aspects of familial thyroid cancer. Oncologist 14:571-577
23. Romei C, Cosci B et al (2011) RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC). Clin Endocrinol (Oxf) 74:241-247